| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4ff9e16ae7a71e7c0920da0a77f0785 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e0e62a84f52f76e8bea588f0a38e169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84013e824ec6cec03cfeafd3f557de1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_287b6109da99737ebaa013e88aa1ee3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab6458fd82cc27293f5c3e84969caa2 |
| publicationDate |
2018-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108144061-A |
| titleOfInvention |
Application of microRNA-210 inhibitors in the preparation of drugs for the treatment of inflammatory skin diseases |
| abstract |
The invention discloses the application of a microRNA-210 inhibitor in the preparation of medicines for treating inflammatory skin diseases. The inventors have proved through a large number of experiments that inhibiting the expression of microRNA-210 in vitro can significantly enhance the expression of its target gene STAT6, thereby inhibiting the proliferation of keratinocytes and the secretion of the chemokine CCL20, and further inhibiting the migration of chemotactic T cells to the skin lesion. Migration, meanwhile, can also inhibit the differentiation of TH 1 and TH 17. Knockout of microRNA‑210 and intralesional injection of a microRNA‑210 inhibitor (cholesterol-modified antagomiR‑210) to specifically inhibit the expression of microRNA‑210 can significantly inhibit mouse skin inflammation and improve T cell immune imbalance. The invention provides a new pathophysiological mechanism for inflammatory skin diseases, and provides a new strategy for preparing medicines for treating inflammatory skin diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108690123-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108690123-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019174413-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11542502-B2 |
| priorityDate |
2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |